Clal Biotechnology Industries Stock Working Capital
| CBI Stock | 46.40 1.60 3.57% |
Clal Biotechnology Industries fundamentals help investors to digest information that contributes to Clal Biotechnology's financial success or failures. It also enables traders to predict the movement of Clal Stock. The fundamental analysis module provides a way to measure Clal Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clal Biotechnology stock.
Clal |
Clal Biotechnology Industries Company Working Capital Analysis
Clal Biotechnology's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Clal Biotechnology Working Capital | 193 M |
Most of Clal Biotechnology's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clal Biotechnology Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Clal Biotechnology Industries has a Working Capital of 193 M. This is 54.66% lower than that of the Biotechnology sector and 64.17% lower than that of the Health Care industry. The working capital for all Israel stocks is 86.94% higher than that of the company.
Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Clal Fundamentals
| Return On Equity | -0.45 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.86) % | |||
| Current Valuation | 89.12 M | |||
| Shares Outstanding | 156.85 M | |||
| Shares Owned By Insiders | 64.58 % | |||
| Price To Earning | (218.28) X | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 2.79 X | |||
| Revenue | 76.96 M | |||
| Gross Profit | 10.72 M | |||
| EBITDA | (98.18 M) | |||
| Net Income | (89.58 M) | |||
| Cash And Equivalents | 94.71 M | |||
| Cash Per Share | 0.59 X | |||
| Total Debt | 52.28 M | |||
| Debt To Equity | 6.30 % | |||
| Current Ratio | 3.67 X | |||
| Book Value Per Share | 0.84 X | |||
| Cash Flow From Operations | (41.33 M) | |||
| Earnings Per Share | (0.57) X | |||
| Target Price | 30.0 | |||
| Number Of Employees | 21 | |||
| Beta | 0.9 | |||
| Market Capitalization | 122.65 M | |||
| Total Asset | 444.92 M | |||
| Retained Earnings | (823 M) | |||
| Working Capital | 193 M | |||
| Current Asset | 254 M | |||
| Current Liabilities | 61 M | |||
| Z Score | -0.2 | |||
| Annual Yield | 0.18 % | |||
| Net Asset | 444.92 M |
About Clal Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clal Biotechnology Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clal Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clal Biotechnology Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Clal Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Clal Biotechnology's short interest history, or implied volatility extrapolated from Clal Biotechnology options trading.
Pair Trading with Clal Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clal Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clal Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Clal Stock
| 0.62 | FVT | Ai Conversation Systems | PairCorr |
The ability to find closely correlated positions to Clal Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clal Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clal Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clal Biotechnology Industries to buy it.
The correlation of Clal Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clal Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clal Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clal Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clal Biotechnology Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |